Business Inquiry

Global：

Email:marketing@medicilon.com

+1(781)535-1428(U.S.)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or refuse these technologies

Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug

2022-07-04

Page View：

On June 23, 2022, Shanghai Medicilon Inc. (Medicilon), Welman Pharmaceutical (Welman) and Shenzhen Mingyu New Drug Research and Development Co., Ltd. (Mingyu) signed a strategic collaboration on preclinical IND application services.

According to the strategic collaboration agreement, Medicilon will assist Welman and Mingyu in advancing the R&D process of one anti-cancer drug with 4 targets, providing better preclinical solutions. At the same time, Welman and Mingyu will give priority to Medicilon as the outsourcing provider of preclinical IND application services, including but not limited to drug discovery, pharmaceutical research, preclinical research and other R&D services.

Medicilon and Welman Pharmaceutical.jpg

About Welman

Welman Pharmaceutical is a leading innovative high-tech pharmaceutical manufacturing enterprise in China. The company's core products are piperacillin sodium sulbactam sodium and cefotaxime sodium sulbactam sodium for injection. Piperacillin sodium sulbactam sodium for injection was launched in 2005, while cefotaxime sodium sulbactam sodium for injection was launched in 2009. Through extensive clinical use and market promotion in recent years, the market demand for the products has grown rapidly.

Email：marketing@medicilon.com

Welman Mingyu Preclinical-IND

Return

Relevant news